NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $30.97 -1.66 (-5.09%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cogent Biosciences Stock (NASDAQ:COGT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cogent Biosciences alerts:Sign Up Key Stats Today's Range$30.91▼$32.8550-Day Range$31.50▼$42.8452-Week Range$12.97▼$43.73Volume761,424 shsAverage Volume2.16 million shsMarket Capitalization$5.37 billionP/E RatioN/ADividend YieldN/APrice Target$51.56Consensus RatingModerate Buy Company Overview Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses its research platform to discover and advance targeted therapies designed to address the underlying drivers of serious medical conditions. Cogent’s lead product candidate is bezuclastinib, an oral, highly selective tyrosine kinase inhibitor designed to target the KIT D816V mutation and other KIT alterations. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both non-advanced and advanced forms of the disease. Cogent Biosciences is headquartered in Boulder, Colorado, and conducts its clinical development activities through studies involving patients and research sites in multiple regions. The company is led by Andrew Robbins, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Cogent Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCOGT MarketRank™: Cogent Biosciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 622nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCogent Biosciences has a consensus price target of $51.56, representing about 66.0% upside from its current price of $31.06.Amount of Analyst CoverageCogent Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cogent Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.23) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -14.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -14.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 8.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.57% of the float of Cogent Biosciences has been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 12.09, which indicates bearish sentiment.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 1.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.27 News SentimentCogent Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cogent Biosciences this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for COGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders6.59% of the stock of Cogent Biosciences is held by insiders.Percentage Held by InstitutionsCogent Biosciences has minimal institutional ownership at this time.Read more about Cogent Biosciences' insider trading history. Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COGT Stock News HeadlinesWedbush Reaffirms Outperform Rating for Cogent Biosciences (NASDAQ:COGT)September 18, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Cogent Biosciences (NASDAQ:COGT)September 17, 2026 | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 23 at 1:00 AM | Profits Run (Ad)Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027September 15, 2026 | rttnews.comCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)September 15, 2026 | globenewswire.comCogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCienciaSeptember 2, 2026 | marketscreener.comMCogent Biosciences: 3 NDAs Create A Time-To-Market MoatAugust 27, 2026 | seekingalpha.comCogent Biosciences, Inc. (COGT)August 14, 2026 | finance.yahoo.comSee More Headlines COGT Stock Analysis - Frequently Asked Questions How have COGT shares performed this year? Cogent Biosciences' stock was trading at $35.52 on January 1st, 2026. Since then, COGT stock has decreased by 12.5% and is now trading at $31.0630. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) posted its quarterly earnings data on Monday, August, 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. When did Cogent Biosciences IPO? Cogent Biosciences (COGT) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,770,000 shares at a price of $12.00-$14.00 per share. Who are Cogent Biosciences' major shareholders? Cogent Biosciences' top institutional investors include BlackRock Inc. (10.16%), Wellington Management Group LLP (2.50%), Assenagon Asset Management S.A. (0.84%) and Elmind Capital LP (0.67%). Insiders that own company stock include Fairmount Funds Management Llc, John Edward Robinson, Jessica Sachs and Evan Kearns. View institutional ownership trends. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Visa (V), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/10/2026Today9/23/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 COGT's financial health is in the Green zone, according to TradeSmith. COGT has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:COGT CIK1622229 Webwww.cogentbio.com Phone(617) 945-5576FaxN/AEmployees258Year Founded2014Price Target and Rating Average Price Target for Cogent Biosciences$51.56 High Price Target$67.00 Low Price Target$35.00 Potential Upside/Downside+66.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$328.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.47% Return on Assets-47.72% Debt Debt-to-Equity Ratio0.48 Current Ratio13.57 Quick Ratio13.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.84 per share Price / Book8.06Miscellaneous Outstanding Shares173,520,000Free Float162,090,000Market Cap$5.37 billion OptionableOptionable Beta0.31 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:COGT) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
